Association of HCV with diabetes mellitus: an Egyptian case-control study

<p>Abstract</p> <p>Background</p> <p>The highest Hepatitis C Virus (HCV) prevalence in the world occurs in Egypt. Several studies from different parts of the world have found that 13% to 33% of patients with chronic HCV have associated diabetes, mostly type II Diabetes Mellitus (DM). In Egypt the prevalence of DM is 25.4% among HCV patients. Therefore, it is important to identify the magnitude of the problem of diabetes in order to optimize the treatment of chronic hepatitis C.</p> <p>Methods</p> <p>The objective of this case-control study was to evaluate the prevalence of DM and other extrahepatic (EH) manifestations among patients with different HCV morbidity stages including asymptomatic, chronic hepatic and cirrhotic patients. In this study, 289 HCV patients older than 18 were selected as cases. Also, 289 healthy controls were included. Laboratory investigations including Liver Function tests (LFT) and blood glucose level were done. Also serological assays including cryoglobulin profile, rheumatoid factor, antinuclear antibody, HCV-PCR were performed.</p> <p>Results</p> <p>Out of 289 HCV cases, 40 (13.84%) were diabetic. Out of 289 healthy controls, 12 (4.15%) were diabetic. It was found that the diabetic HCV group mean age was [48.1 (± 9.2)]. Males and urbanians represented 72.5% and 85% respectively. Lower level of education was manifested in 52.5% and 87.5% were married. In the nondiabetic HCV group mean age was [40.7 (± 10.4)]. Males and urbanians represented 71.5% and 655% respectively. secondary and higher level of education was attained in 55.4% and 76.7% were married. Comparing between the diabetic HCV group and the non diabetic HCV group, age, residence and alcohol drinking were the only significant factors affecting the incidence of diabetes between the two groups. There was no significant difference regarding sonar findings although cirrhosis was more prevalent among diabetic HCV cases and the fibrosis score was higher in diabetic HCV patients than among the non diabetic HCV cases.</p> <p>Conclusion</p> <p>The diabetic patients in the HCV group were older, more likely to have a history of alcohol drinking than the non diabetic HCV cases. Age and alcohol drinking are factors that could potentially contribute to the development of type 2 diabetes. Logistic regression analyses showed that age and residence in urban regions were the predictive variables that could be associated with the presence of diabetes. Alcohol consumption was not a significant predictive factor.</p

Studio di campioni di impedenza a temperature criogeniche nel dominio delle microonde

Consiglio Nazionale delle Ricerche - Biblioteca Centrale - P.le Aldo Moro, 7, Rome / CNR - Consiglio Nazionale delle RichercheSIGLEITItal

Misura della permettivita' dielettrica di materiali in campioni sottili nella regione delle microonde

Consiglio Nazionale delle Ricerche - Biblioteca Centrale - P.le Aldo Moro, 7, Rome / CNR - Consiglio Nazionale delle RichercheSIGLEITItal

Coke location in microporous and hierarchical ZSM-5 and the impact on the MTH reaction

The deactivation and reactivation of microporous and hierarchical ZSM-5 zeolites have been studied in the methanol-to-hydrocarbon (MTH) reaction. The hierarchical ZSM-5 was synthesized via the desilication reassembly technique using cetyltrimethylammonium bromide as a surfactant. The catalysts differed significantly in the catalytic behavior after the reactivation procedure. This is ascribed to a different coke location in the deactivated catalysts arising from the difference in the porosity. The microporous ZSM-5 showed a coke gradient over the particle with a stronger accumulation of carbonaceous species in the outer particle layers, whereas a homogeneous coke distribution was observed for the deactivated hierarchical ZSM-5. Due to the diverging coke distribution, the irreversible damage of the zeolitic structure caused by reactivation differs for both catalysts. This fact is assumed to be the reason for the different deactivation/reactivation behaviors of these two zeolitic systems

Impact of Insulin Resistance on HCV Treatment Response and Impact of HCV Treatment on Insulin Sensitivity Using Direct Measurements of Insulin Action

OBJECTIVE: Insulin resistance, as measured by surrogate markers, is associated with lower response to hepatitis C virus (HCV) therapy and may improve with HCV eradication. We prospectively evaluated the impact of directly measured insulin resistance and abnormal glucose metabolism on achieving sustained virologic response (SVR) with HCV therapy and assessed whether SVR results in improved insulin sensitivity and fasting glucose. RESEARCH DESIGN AND METHODS: A total of 50 noncirrhotic, nondiabetic, HCV-infected patients (27 untreated, 23 treated with pegylated interferon/ribavirin, nonrandomized) underwent clinical and histologic evaluation and 75-g oral glucose tolerance test. Insulin sensitivity was assessed directly with insulin suppression test by measuring steady-state plasma glucose (SSPG) concentration during a 240-min infusion of octreotide, glucose, and insulin. Of the subjects, 43 had at least one follow-up evaluation. RESULTS: Patient characteristics were median age 48, 57% male, and 52% white. SVR was achieved in 61% (14 of 23) of treated subjects. SVR was independently associated with HCV genotypes 2 and 3 (odds ratio 8.8 [95% CI 1.2–61.7]) but was not strongly associated with insulin sensitivity. When controlling for elapsed time between measurements, being on interferon, and BMI, SSPG decreased by 36 mg/dL (−88 to 16) in those with SVR and decreased by 28 mg/dL (−93 to 38) in those without SVR, compared with the untreated group. BMI (coefficient 9.1 per 5 units; 95% CI 5.3–12.9) and interferon use (coefficient 56; 95% CI 6.8–105) were associated with SSPG. CONCLUSIONS: Insulin resistance does not appear to be strongly associated with SVR. HCV therapy may improve insulin resistance regardless of virologic response; however, BMI and interferon use were clearly associated with insulin resistance

Design of the third-generation lead-based neutron spallation target for the neutron time-of-flight facility at CERN

The neutron time-of-flight (n_TOF) facility at the European Laboratory for Particle Physics (CERN) is a pulsed white-spectrum neutron spallation source producing neutrons for two experimental areas: the Experimental Area 1 (EAR1), located 185 m horizontally from the target, and the Experimental Area 2 (EAR2), located 20 m above the target. The target, based on pure lead, is impacted by a high-intensity 20-GeV/c pulsed proton beam. The facility was conceived to study neutron-nucleus interactions for neutron kinetic energies between a few meV to several GeV, with applications of interest for nuclear astrophysics, nuclear technology, and medical research. After the second-generation target reached the end of its lifetime, the facility underwent a major upgrade during CERN's Long Shutdown 2 (LS2, 2019-2021), which included the installation of the new third-generation neutron target. The first- and second-generation targets were based on water-cooled massive lead blocks and were designed focusing on EAR1, since EAR2 was built later. The new target is cooled by nitrogen gas to avoid erosion-corrosion and contamination of cooling water with radioactive lead spallation products. Moreover, the new design is optimized also for the vertical flight path and EAR2. This paper presents an overview of the target design focused on both physics and thermomechanical performance, and includes a description of the nitrogen cooling circuit and radiation protection studies